#Palivizumab
LightNews LightNews
cbammermd.bsky.social
Ziresovir sind in der Pipeline, monoklonale Antikörper wie Palivizumab und Nirsevimab stehen bereits zur Verfügung.
4/9
February 10, 2026 at 11:13 AM
castltrastondrs.bsky.social
vaccinated individuals inform the design of improved vaccine antigens and regimens.
Some monoclonal antibodies, such as palivizumab and nirsevimab, are already used or in clinical trials for RSV prophylaxis, while similar efforts for hMPV are ongoing but remain in preclinical stages
January 19, 2026 at 6:47 AM
tom.medsky.social
The previous generation monoclonal antibody, palivizumab, had strictly defined high risk indications such as prematurity and congenital heart disease. This was due to the high cost and short duration of protection.

We also had a functional ACIP at that time.
January 11, 2026 at 5:14 PM
cjphrcsp.bsky.social
Check out our Editor’s Choice in the latest issue of @cjphrcsp.bsky.social Volume 116, Issue 5 Use of the moving epidemic method to guide the launch of palivizumab immunization campaigns for respiratory syncytial virus in Québec, Canada (Raad et al.) link.springer.com/article/10.1...
December 17, 2025 at 7:35 PM
pschochet.bsky.social
I concur. As a practicing pediatric pulmonologist for almost 30 years I am amazed how effective palivizumab and now nirsevimab have been in reducing the hospitalization rates due to RSV in babies. Nirsevimab is given to all babies and works. I’ve not seen sig side effects from either medication
December 10, 2025 at 3:59 AM
pwhickey.bsky.social
I had plenty of criticism for Cody Meissner’s positions related to pediatric Covid vaccines, but he’s a Peds ID Doc with deep clinical trials experience (instrumental work on RSV prevention with palivizumab - synagis™️).
He called out the bullshit pretense of today’s ACIP meeting. I hope he resigns.
September 18, 2025 at 11:11 PM
nejm.org
RSV remains a severe infection in infants and children. In this report, data on the activity of clesrovimab, a long-lasting RSV monoclonal antibody, are described as compared with palivizumab. Full interim results for the SMART phase 3 trial: nej.md/4poVkDE

#MedSky #IDSky #PedSky
Table 2. Incidence of RSV-Associated Secondary End Points in RSV Season 1.
September 17, 2025 at 9:45 PM
marcveld.bsky.social
Ten eerste zijn er meedrere producten op de markt; Nirsevimab (AZ/Sanofi), Palivizumab (Synagis) en Clesrovimab (Merck). Het klopt dat dit monoclonale antilichamen zijn. Ideal, en dat zal in de toekomst misschien ook gebeuren, worden er meer dan 1 tegelijk gegeven.

2/8
September 9, 2025 at 12:54 PM
cochranefrance.bsky.social
👶 #Palivizumab dans la prévention des #infections graves dues au #VirusRespiratoireSyncytial chez les #enfants

📚 MàJ revue @cochrane.org (6 ECR, 3 611 enfants)

🔗 Lire le résumé t.ly/xnAGd

#cochranereview #santédelenfant #poumons #voiesrespiratoires #VRS #maladiesinfectieuses #médecine #santé
September 9, 2025 at 12:00 PM
lbscience.org
התכשיר החדש מחליף את תכשיר הנוגדנים הקודם Synagis (או palivizumab) שמשך פעילותו כחודש בלבד ולכן ניתן בחמש מנות חודשיות רק לפגים ויילודים בסיכון. ⬇️
September 7, 2025 at 6:45 AM
canadahealthwatch.ca
Manitoba updating RSV immunization program this fall, but not committing to universal coverage https://www.cbc.ca/news/canada/manitoba/rsv-immunization-update-1.7610653

𝗚𝗲𝘁 𝘄𝗲𝗲𝗸𝗹𝘆 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 ⇢ CanadaHealthwatch.ca/newsletter
As of Oct. 1, Manitoba's RSV program will switch from providing palivizumab, a monthly antibody treatment, to nirsevimab, a single-dose, injectable treatment. However, it will still only be available to infants deemed to be at high risk from RSV infection.
August 19, 2025 at 2:55 AM
marioamacedo.bsky.social
Mas há mais na ignorância. Há anos que se utiliza o Palivizumab contra o vsr em grupos de risco. Porquê a troca? Porque o Palivizumab precisa de 5 doses durante a época epidemica, o novo precisa de 1 dose.
O nirsevimab é caro por dose, mas mais barato por criança.
August 11, 2025 at 4:27 PM
nppguk.bsky.social
An RCPCH webinar is being arranged on Thurs 21st August 12.30-1.30pm for any healthcare professionals that would like to understand and know more around the change to using nirsevimab instead of palivizumab this year.
Details & registration can be found at www.rcpch.ac.uk/education-ca...
RCPCH Webinar: RSV update 2025 - Changes to monoclonals for preterm infants
In July 2025 it was announced that high efficacy, single dose nirsevimab immunisation will replace the NHS use of monthly palivizumab injections for infants at high risk of severe respiratory syncytia...
www.rcpch.ac.uk
July 29, 2025 at 11:30 AM
cochraneus.bsky.social
RSV causes 33M+ child infections yearly. Palivizumab helps but how well?

✅ IV/IM: may lower infection & later issues
🚫 Nasal: no benefit to long-term symptoms
⚖️ Little/no effect on death or side effects
📚 More research needed.
🔗 www.cochranelibrary.com/cdsr/doi/10....

@cochrane.org
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children - Garegnani, L - 2025 | Cochrane Library
Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.
www.cochranelibrary.com
July 28, 2025 at 3:33 PM
nursinginpractice.bsky.social
Nirsevimab – administered during care by a specialist neonatal team – will replace monthly injections of palivizumab previously offered to some babies.
Premature babies to receive six months’ protection against RSV in single injection
Vulnerable premature babies who need extra protection against RSV may receive six months’ protection in a long-lasting single injection.
buff.ly
July 24, 2025 at 7:59 AM
enirenberg.bsky.social
Meissner is satisfied with the available data on the safety as is the RSV work group. Regarding concomitant administration with vaccines, there is no interference with vaccines on the schedule observed from administration of palivizumab, the previous generation passive immunoprophylaxis against...
June 26, 2025 at 12:43 PM
enirenberg.bsky.social
Resource Use- in terms of the economic analysis, it does not appear that clesrovimab would be truly cost-saving with regard to ICERs, but the work group felt that this was a reasonable use of resources at the proposed price points
One-way sensitivity analysis: 50% coverage with clesrovimab among an annual US birth cohort1 Incremental Cost-Effectiveness Ratio ($/QALY gained) $O $50,000 $100,000 $150,000 $200,000 $250,000 Disease-Specific Inpatient Costs (per Inpatient Case) RSV OALYS Lost Clesrovimab cost/dose Proportion of Outpatient Visits With an LRTI Diagnosis Age 0-5 Months Proportion of Hospitalizations With an LRTI Diagnosis Age 0-5 Months Proportion of Outpatient Visits With an LRTI Diagnosis Age 6-11 Months Fraction Receiving Palivizumab Natural History Outpatient Efficacy RSV Mortality Per Hospitalization Age 0-5 Months Efficacy 6-10 months Base case: ~$105,000 $/QALY gained • Low = High 1. Estimates provided by an updated UM-CDC model, where updates included VE and cost/dose. Original model and methods described here: Hutton et al, Pediatrics (2024): https://doi.org/10.1542/peds.2024-066461 Abbreviations: QALY: quality adjusted life year | LRTI: lower respiratory tract infection 40| Resource Use • Is clesrovimab use among infants under 8 months of age born during or entering their first RSV season a reasonable and efficient allocation of resources with an estimated cost of $458 on average ($365 VFC / $560 other) per dose? No Probably No Probably Yes Yes Varies Don't know Majority opinion Abbreviations: VFC: Vaccines for Children Minority opinion |
June 25, 2025 at 8:34 PM
enirenberg.bsky.social
Dr. Daley is now presenting on safety findings for nirsevimab:
www.cdc.gov/acip/downloa...

There were no significant signals of safety issues in the prelicensure trials. These data are from the VSD looking at 36,719 infants receiving nirsevimab via a self-controlled risk interval study.
Nirsevimab overview • Long-acting monoclonal antibody, licensed for prevention of lower respiratory tract disease in infants caused by RSV • Recommendations for use: oAll infants aged birth through <8 months (if no RSV vaccine during pregnancy) o High-risk infants aged 8-19 months • High efficacy in phase 3 trial, high effectiveness post-licensure • Severe shortage during 2023-2024 season • RSV prevention (nirsevimab or vaccine): 72% uptake in VSD Nirsevimab Overview Nirsevimab Safety Surveillance Ref: 1) Muller WJ et al, N Engl J Med 2023;388(16):1533-1534; 2) Jones JM et al, MMWR 2023;72(34):920-925. 3) Moline HL et al, JAMA Pediatr 2025;179(2):179-187. 4) Irving SA et al, Pediatrics 2025;155(6):e2024070240. Nirsevimab Safety, Clinical trials • Across 3 randomized trials: n=3,184 received nirsevimab, n=1,284 received placebo, n=304 received palivizumab • Adverse events generally balanced among infants who received nirsevimab versus comparator • Adverse events of special interest included 7 nirsevimab-exposed infants with rashes, primarily papular or maculopapular • No anaphylaxis, no serious hypersensitivity-type reactions reported • No immune complex diseases reported Nirsevimab Safety, Clinical Trials Nirsevimab Safety Surveillance Ref: 1) Muller WJ et al, N Engl J Med 2023;388(16):1533-1534. 2) Mankad VS et al, Pathogens 2024;13(6):503. Safety Results, VSD, 2023-2024 Season • Received nirsevimab, n=36,719 • Adverse events monitored, self-controlled risk interval (SCRI): oAll analyses stratified by age group (neonates; infants) oSeizures, ITP, drug reaction, fever or sepsis (neonate cohort only) o None showed elevated risk • Exposure-dependent events: monitored case counts oAnaphylaxis: no cases detected o Non-anaphylactic allergic reactions: urticaria, often same day as nirsevimab Methods Overview • Setting: all VSD data-contributing sites • Population: all infants 0 days through <8 months of life who received nirsevimab between October 1, 2024, and February 1, 2025 • Same-day vaccines: study included all nirsevimab-exposed infants, regardless of whether they received vaccines same day as nirsevimab • Health insurance enrollment: through control window • Study design: primarily used SCRI • Excluded infants born to someone who received RSV vaccine during pregnancy KAISER PERMANENTE INSTITUTE FOR HEALTH RESEARCH Nirsevimab Safety Surveillance SING KAISER PERMANENTE Institute for Health Research Self-Controlled Designs in Safety Studies • Self-controlled risk interval is a form of self-controlled case series study • Commonly used design in vaccine safety studies • Rationale: exposed (to vaccine, or to nirsevimab) often differ in important characteristics from unexposed; these characteristics typically not measured in electronic health record (EHR) data and can confound safety assessments • These are within-individual designs; control for measured and unmeasured confounders that do not vary over time; example, a prevalent chronic condition Ref: 1) Nie X et al, Expert Rev Vaccines 2022;21 (3):313-324. 2) Weldeselassie YG et al, Epidemiol Infect 2011;139(12):1805- 17. 3) Li R et al, J Biopharm Stat 2016;26(4):686-93. 4) Bots SH et al, Am J Epidemiol. 2025;194(1):208-219. KAISER PERMANENTE INSTITUTE FOR HEALTH RESEARCH Nirsevimab Safety Surveillance Slide 11 Slide 12 Age Effects • Diagnoses in first month of life often related to pregnancy, delivery, newborn-specific conditions • Health care utilization different in first month of life • Lags in health insurance enrollment • With the exception of birth dose of hepatitis B vaccine, earliest all other vaccines recommended: 38 days of age • Separate safety analyses: • Newborns: defined as 0 days through 37 days of age o Infants (out of newborn period): 38 days through <8 months of age
June 25, 2025 at 8:08 PM
pabloestrellap.bsky.social
Hasta hace poco, solo los bebés con factores de riesgo recibían una protección especial: un anticuerpo llamado palivizumab, que requería cinco dosis.
Pero en 2023, España dio un paso más: introdujo un nuevo anticuerpo para todos los recién nacidos: #nirsevimab. 💉
June 16, 2025 at 7:13 AM
castltrastondrs.bsky.social
#Medsky🧪 #IDSky #pedsky #pharmasky #immunosky #episky #publichealth #Palivizumab may be considered for the prevention of RSV infection in at-risk infants below 1 year of age :
1. Infants at risk for recurrent #pneumonia due to respiratory tract abnormalities or neuromuscular diseases.
June 12, 2025 at 1:07 PM
contagionlive.bsky.social
RSV infects 90% of children by age 2 and causes over 3 million hospitalizations annually. Palivizumab & nirsevimab are injectable monoclonal antibodies used for prevention in infants. #IDsky #MEDsky #PEDSsky

Read more from Contemp. Peds. May 2025 journal: www.contagionlive.com/view/rsv-pro...
RSV Prophylaxis: Palivizumab, Nirsevimab, and More
Current prevention strategies include two injectables for infants and young children, namely palivizumab and nirsevimab.
www.contagionlive.com
May 9, 2025 at 1:30 PM
esmiravet.bsky.social
Argentina / Salud | Distribuyen en todo el país medicación para prevenir el virus sincicial respiratorio en prematuros

El Ministerio de Salud de la Nación dio inicio a la distribución del Palivizumab a todas las jurisdicciones del país. Este anticuerpo monoclonal permite prevenir la infección…
Argentina / Salud | Distribuyen en todo el país medicación para prevenir el virus sincicial respiratorio en prematuros
El Ministerio de Salud de la Nación dio inicio a la distribución del Palivizumab a todas las jurisdicciones del país. Este anticuerpo monoclonal permite prevenir la infección respiratoria baja severa por virus sincicial respiratorio (VSR) y la morbimortalidad infantil asociada, en los niños nacidos con hasta 32 semanas de edad gestacional o con un peso de hasta 1.500 g. y en aquellos que presenten cardiopatías congénitas severas. La entrega a las jurisdicciones se organizó en dos etapas y de acuerdo al stock con el que cuentan para iniciar la inmunización. En una primera instancia, iniciada la semana anterior, se distribuirán más de 1.100 ampollas en la Ciudad Autónoma de Buenos Aires y en la Provincia de Buenos Aires y, a partir del 5 de mayo, se realizará la entrega de más de 1.700 ampollas al resto de las jurisdicciones.
voxpopuli.com.ar
May 4, 2025 at 2:36 PM
pidjournal.bsky.social
Factors Associated With Hospitalization, Length of Stay, and Hospital Expenditures for Respiratory Syncytial Virus Infection in Japanese Infants and Children According to Palivizumab-indicated Underlying Conditions: The LIFE Study

by Inoue, Masako

journals.lww.com/pidj/fulltex...
Factors Associated With Hospitalization, Length of Stay,... : The Pediatric Infectious Disease Journal
nfection severity remains unclear. This study examined RSV infection severity and hospitalization outcomes in Japanese infants and children according to palivizumab eligibility and identified their as...
journals.lww.com
February 14, 2025 at 9:14 AM
tim-van-hasselt.bsky.social
Nice paper looking at regional changes in RSV hospitalisation in Nova Scotia, Canada, when palivizumab eligibility stopped for 30-32 week babies. From 0 hospitalisation to 9% in this group.

Important to monitor epidemiology & potential associations

www.thieme-connect.com/products/ejo...
Increased Respiratory Syncytial Virus-Associated Hospitalizations and Ambulatory Visits in Very Preterm Infants in the First Year of Life following Discontinuation of Access to Palivizumab
Thieme E-Books & E-Journals
www.thieme-connect.com
February 10, 2025 at 10:54 AM